Accessibility Menu
Journey Medical Stock Quote

Journey Medical (NASDAQ: DERM)

$7.25
(-1.4%)
-0.10
Price as of October 22, 2025, 3:01 p.m. ET

KEY DATA POINTS

Current Price
$7.25
Daily Change
(-1.4%) $0.10
Day's Range
$7.2 - $7.58
Previous Close
$7.35
Open
$7.37
Beta
0.50
Volume
67,035
Average Volume
145,364
Market Cap
193.4M
Market Cap / Employee
$7.35M
52wk Range
$3.54 - $8.9
Revenue
-
Gross Margin
0.60%
Dividend Yield
N/A
EPS
-$0.39
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Journey Medical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
DERM+16.3%N/AN/A-23%
S&P+15.06%+95.03%+14.29%+44%

Journey Medical Company Info

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Financial Health

General

Q2 2025YOY Change
Revenue$15.01M1.0%
Gross Profit$9.01M8.3%
Gross Margin60.00%4.0%
Market Cap$167.26M48.2%
Market Cap / Employee$4.08M0.0%
Employees41-29.3%
Net Income-$3.80M-12.9%
EBITDA-$1.79M14.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$20.29M-15.1%
Accounts Receivable$15.64M49.5%
Inventory12.932.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$21.43M8.5%
Short Term Debt$3.85M25.7%

Ratios

Q2 2025YOY Change
Return On Assets-11.94%-13.2%
Return On Invested Capital-37.74%-15.9%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$0.94M81.8%
Operating Free Cash Flow-$0.94M81.8%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book10.017.426.517.70-11.28%
Price to Sales2.011.542.372.97104.26%
Price to Tangible Book Value-15.36-11.72-11.08-17.923.97%
Price to Free Cash Flow TTM21.2461.77-
Enterprise Value to EBITDA-55.73-68.77-61.44-96.2179.90%
Free Cash Flow Yield4.7%1.6%-
Return on Equity-129.6%-72.6%-48.1%-57.2%-483.51%
Total Debt$21.07M$25.71M$25.17M$25.28M10.83%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.